Make It Simple: (SR-A1+TLR7) Macrophage Targeted NANOarchaeosomes

Area of Science:

• Biochemistry
• Immunology
• Nanotechnology

Background:

• Hyperhalophilic archaea produce unique archaeolipids, forming stable nanoarchaeosomes (nanoARC) with targeting capabilities.
• Imiquimod (IMQ), a TLR7 agonist, interacts strongly with archaeolipid bilayers, suggesting potential for targeted drug delivery.

Purpose of the Study:

• To hypothesize and investigate nanoARC from *Halorubrum tebenquichense* as efficient carriers for IMQ.
• To evaluate the enhanced immunogenicity and reduced side effects of nanoARC-IMQ compared to conventional liposomes.

Main Methods:

• Nanoarchaeosomes (nanoARC) were synthesized and loaded with IMQ, achieving high drug encapsulation.
• In vitro studies assessed TNF-α and IL-6 secretion by macrophages treated with nanoARC-IMQ.
• In vivo studies in mice evaluated delayed-type hypersensitivity (DTH) response and antibody titers after co-administration with leishmania antigens (TLA).

Main Results:

• NanoARC-IMQ exhibited significantly higher IMQ loading capacity compared to soyPC liposomes (LIPO-IMQ).
• In vitro, nanoARC-IMQ induced greater TNF-α and IL-6 secretion from macrophages.
• In vivo, nanoARC-IMQ significantly boosted DTH response and antigen-specific IgG titers, indicating enhanced immunogenicity with a Th2 bias.

Conclusions:

• NanoARC serve as effective carriers for IMQ, leveraging scavenger receptor A1 (SR-A1) mediated uptake by macrophages.
• This targeted delivery enhances IMQ's immunomodulatory effects specifically in TLR7-expressing cells, potentially reducing systemic toxicity.
• NanoARC-IMQ represents a promising platform for developing more effective immunotherapies.